News & Views

  • Lab news: FDA approves new cancer drug
    New drug reduced progression rate in cancer suffers

Lab news: FDA approves new cancer drug

May 09 2011 Read 1691 Times

The US Food and Drug Administration (FDA) has approved a new drug devised by scientists to treat a rare type of cancer.

Everolimus (Afinitor, Novartis) tablets are now permitted for use on patients with progressive neuroendocrine tumors (NET) of pancreatic origin (PNET) that cannot be treated through surgery or have spread throughout the body, Drugs Topics reported.

Scientists found that 410 patients with metastatic or locally advanced disease treated with Afinitor doubled their period without tumour growth, from an average of 4.6 to 11 months, and reduced cancer progression risk by 65 per cent.

This is the first new treatment approved for patients with advanced PNET for nearly 30 years.

Dr James C Yao, associate professor and deputy chair of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, told Drug Topics that the approval is an important advancement for the treatment of the rare cancer.

Cancer Research reported that about 7,680 people were diagnosed with pancreatic cancer in 2007 in the UK, which equates to 21 people every day.ADNFCR-3196-ID-800523853-ADNFCR

Digital Edition

Labmate UK & Ireland April2021

April 2021

In This Edition Articles - Seats at the table to shape the industry’s future - Battling biohazardous liquid laboratory waste Laboratory Products - Two New Powerful Stirrers Announced...

View all digital editions


ChemBio Finland - Virtual preview

Apr 28 2021 Virtual event

SETAC Europe

May 02 2021 Virtual conference

AOCS Annual Meeting & Expo

May 03 2021 Online event


May 09 2021 Fort Worth, Tx, USA

View all events